Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials. (nature.com)

Authors: Platzbecker AS … Platzbecker U Journal: Communications Medicine Published: 2026-09-16 DOI: https://doi.org/10.1038/s43856-026-01885-z